Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results From VALOR-HCM
Circulation · 13.05.2025 · 151 (19) · 1378-1390
DOI: 10.1161/circulationaha.124.072445 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Circulation, erschienen am 13.05.2025. Verfasst von Milind Y Desai und 19 weiteren Autor:innen. Beteiligte Einrichtung: Hypertrophic Cardiomyopathy Center (M.Y.D., N.G.S.), Cleveland Clinic, OH. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic, Uracil. Die Arbeit wurde bisher 78-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol Myers Squibb Foundation.
Abstract (Originalsprache)
BACKGROUND: In severely symptomatic patients with obstructive hypertrophic cardiomyopathy (HCM), VALOR-HCM trial (Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy [URL: https://clinicaltrials.gov ; Unique identifier: NCT04349072]) reported that mavacamten reduced the short-term need for septal reduction therapy (SRT). The current report examined the longer-term effect of mavacamten through end of treatment at week 128. METHODS: A double-blind randomized placebo-controlled multicenter trial at 19 sites in the United States included symptomatic obstructive HCM patients referred for SRT (enrollment July 2020 through October 2021). The group initially randomized to mavacamten continued the drug for 128 weeks and the placebo to mavacamten group from week 16 to 128 (112-week exposure). Dose titrations were performed using echocardiographic left ventricular outflow tract gradient and left ventricular ejection fraction measurements. The principal end point was proportion of patients proceeding with SRT or remaining guideline-eligible at week 128. RESULTS: At week 128, 17 of 108 (15.7%) patients in the total study sample met the composite end point (7 underwent SRT, 1 was SRT-eligible, and 9 SRT-status unevaluable). Additionally, 87 of 108 (80.5%) patients demonstrated ≥1 New York Heart Association class improvement by week 128, and 52 of 108 (48.1%) demonstrated ≥2, with a sustained reduction in resting and Valsalva left ventricular outflow tract gradients of 38.2 mm Hg and 59.4 mm Hg, respectively. Ninety-five of 108 (88%) patients transitioned to commercial mavacamten. Overall, 15 of 108 (13.8%) patients (5.41 per 100 patient-years) had an left ventricular ejection fraction
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hypertrophic Cardiomyopathy Center (M.Y.D., N.G.S.), Cleveland Clinic, OH.
- Department of Cardiovascular Medicine, Cleveland Clinic Coordinating Center for Clinical Research (M.Y.D., K.W., P.C.C., S.E.N.), Cleveland Clinic, OH.
- Heart Vascular and Thoracic Institute (M.Y.D., K.W., P.C.C., S.E.N.), Cleveland Clinic, OH.
- Division of Cardiology, University of Pennsylvania, Philadelphia (A.O.).
- Departments of Cardiovascular Diseases (J.B.G.), Mayo Clinic, Rochester, MN.
- Department of Internal Medicine, University of Michigan, Ann Arbor (S.S.).
ORCID-Profile: Kathy Wolski, Anjali Owens, Jeffrey B Geske, Sara Saberi, Andrew Wang, Mark Sherrid, Paul C Cremer, Neal K Lakdawala, Albree Tower-Rader, Srihari S Naidu, Nicholas G Smedira, Hartzell Schaff, Amy J Sehnert, Steven E Nissen
Förderung
- Bristol Myers Squibb Foundation
Zitieren
APA
Desai, M. Y., Wolski, K., Owens, A., Geske, J. B., Saberi, S., Wang, A., Sherrid, M., Cremer, P. C., Lakdawala, N. K., Tower-Rader, A., Fermin, D., Naidu, S. S., Smedira, N. G., Schaff, H., Gong, Z., Mudarris, L., Lampl, K., Sehnert, A. J., Nissen, S. E., & VALOR-HCM Investigators (2025). Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results From VALOR-HCM. Circulation, 151(19), 1378-1390. https://doi.org/10.1161/circulationaha.124.072445
Vancouver
Desai MY, Wolski K, Owens A, Geske JB, Saberi S, Wang A, et al. Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results From VALOR-HCM. Circulation. 2025;151(19):1378-1390. doi:10.1161/circulationaha.124.072445
BibTeX
@article{Desai2025,
author = {Desai, Milind Y and Wolski, Kathy and Owens, Anjali and Geske, Jeffrey B and Saberi, Sara and Wang, Andrew and Sherrid, Mark and Cremer, Paul C and Lakdawala, Neal K and Tower-Rader, Albree and Fermin, David and Naidu, Srihari S and Smedira, Nicholas G and Schaff, Hartzell and Gong, Zhiqun and Mudarris, Lana and Lampl, Kathy and Sehnert, Amy J and Nissen, Steven E and VALOR-HCM Investigators, VALOR-HCM Investigators},
title = {Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results From VALOR-HCM},
journal = {Circulation},
year = {2025},
volume = {151},
number = {19},
pages = {1378--1390},
doi = {10.1161/circulationaha.124.072445}
}
EUVIMED